Spots Global Cancer Trial Database for acute lymphoid leukemia
Every month we try and update this database with for acute lymphoid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Erwinase Master Treatment Protocol | NCT00590915 | Leukemia, Acute... Acute Lymphoid ... | Erwinia L-aspar... | - | Phoenix Children's Hospital | |
| Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia | NCT03367299 | Acute Lymphoid ... Philadelphia Ch... | Chemotherapy + ... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Latin American Real-world Study in Acute Leukemia | NCT05166135 | Acute Myeloid L... Acute Lymphoid ... | 18 Years - 99 Years | Pfizer | ||
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | NCT05316701 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related... | Orca-T Standard-of-Car... | 18 Years - 65 Years | Orca Biosystems, Inc. | |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | NCT05322850 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Acute Undiffere... Chronic Myeloid... Chronic Myeloid... Chronic Myeloid... | Orca-Q | - 50 Years | University of Florida | |
| Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | NCT03792633 | Acute Lymphoid ... | huCART19 | 3 Months - 29 Years | University of Pennsylvania | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery | NCT02767388 | Myelodysplastic... Effects of Chem... Mild Cognitive ... Multiple Myelom... Non-hodgkin Lym... Chronic Lymphoc... Acute Lymphoid ... Chronic Myeloid... Acute Myeloid L... | 19 Years - 80 Years | University of Nebraska | ||
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | NCT02605460 | Acute Myeloid L... Acute Lymphoid ... | Busulfan Cyclophosphamid... CXCR4 Antagonis... Hematopoietic S... | 18 Years - 60 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Muscle Dysfunction in Patients With Haematological Diseases | NCT05150561 | Hematologic Dis... Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Lymphoma | 18 Years - | Rigshospitalet, Denmark | ||
| A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | NCT02454270 | Leukemia, Lymph... Lymphoma, Large... Lymphoma, Folli... Lymphoma, Mantl... Precursor Cell ... | Part 1 (Dose Es... Part 2 (Dose Ex... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL) | NCT00983138 | Acute Lymphoid ... | recombinant asp... | - 364 Days | medac GmbH | |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | NCT02294552 | Acute Myeloid L... Acute Lymphoid ... Lymphoma Myelodysplastic... Chronic Lymphoc... Immune System D... | Cyclophosphamid... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Allogeneic hema... | 18 Years - 65 Years | St. Petersburg State Pavlov Medical University | |
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy | NCT04778579 | Acute Lymphoid ... | ARI-0001 cells | 18 Years - 70 Years | Institut d'Investigacions Biomèdiques August Pi i Sunyer | |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | NCT02458235 | Acute Myelogeno... Acute Lymphoid ... Juvenile Myelom... Myelodysplastic... | azacitidine donor lymphocyt... | - 29 Years | University of California, San Francisco | |
| H19 in Acute Lymphoblastic Leukemia. | NCT05943093 | Acute Lymphoid ... | 2 Months - 70 Years | Assiut University | ||
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | NCT06427330 | Acute Lymphoid ... | Inotuzumab ozog... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | NCT05316701 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related... | Orca-T Standard-of-Car... | 18 Years - 65 Years | Orca Biosystems, Inc. | |
| Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL) | NCT00983138 | Acute Lymphoid ... | recombinant asp... | - 364 Days | medac GmbH | |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy | NCT00469729 | Hematologic Mal... Acute Myeloid L... Lymphoid Leukem... Chronic Myeloid... Hodgkin's Disea... Non-Hodgkin's L... Myelodysplastic... | StemEx® | 12 Years - 55 Years | Gamida Cell -Teva Joint Venture Ltd. | |
| The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents | NCT02953730 | Acute Lymphoid ... | PEG-rhG-CSF | - 18 Years | ChineseAMS | |
| PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT | NCT04669210 | Graft-versus-ho... Stem Cell Trans... Acute Myeloid L... Acute Lymphoid ... | Ruxolitinib Tacrolimus Mycophenolate M... | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | NCT05827549 | Acute Lymphoid ... | Blincyto | 1 Year - 22 Years | Asan Medical Center | |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | NCT05322850 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Acute Undiffere... Chronic Myeloid... Chronic Myeloid... Chronic Myeloid... | Orca-Q | - 50 Years | University of Florida | |
| H19 in Acute Lymphoblastic Leukemia. | NCT05943093 | Acute Lymphoid ... | 2 Months - 70 Years | Assiut University | ||
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis | NCT01749111 | Acute Myelogeno... Acute Lymphoid ... Myeloproliferat... Myelodysplastic... Chronic Myeloid... Chronic Myelomo... | ARM A Cyclophos... ARM B Calcineur... | 18 Years - 60 Years | Hospital Israelita Albert Einstein | |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | NCT04013685 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Acute Leukemia Blastic Plasmac... Chronic Myeloid... | Orca-T | 18 Years - 75 Years | Orca Biosystems, Inc. | |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | NCT02413021 | Acute Myeloid L... Acute Lymphoid ... | Cytarabine Deferasirox | 15 Years - | Isfahan University of Medical Sciences | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | NCT01344876 | Multiple Myelom... Non-Hodgkin Lym... Acute Myeloid L... Acute Lymphoid ... Chronic Myeloid... | OPB-51602 | 20 Years - 75 Years | Otsuka Pharmaceutical Co., Ltd. | |
| Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia | NCT02345915 | Leukemia, Myelo... Acute Lymphoid ... | Blood sample Electrocardiogr... | 18 Years - 30 Years | Institut Paoli-Calmettes | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL) | NCT00983138 | Acute Lymphoid ... | recombinant asp... | - 364 Days | medac GmbH | |
| Study of the Medullary Microenvironment in Acute Childhood Leukemia | NCT05792007 | Acute Lymphoid ... Acute Myeloid L... | Biological samp... Biological samp... | 1 Year - 15 Years | University Hospital, Tours | |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. | NCT01743989 | Philadelphia Ch... | Nilotinib | 18 Years - | Novartis | |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | NCT05827549 | Acute Lymphoid ... | Blincyto | 1 Year - 22 Years | Asan Medical Center | |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | NCT05316701 | Acute Myeloid L... Acute Lymphoid ... Mixed Phenotype... Undifferentiate... Myelodysplastic... Acute Leukemia Therapy-Related... | Orca-T Standard-of-Car... | 18 Years - 65 Years | Orca Biosystems, Inc. | |
| Latin American Real-world Study in Acute Leukemia | NCT05166135 | Acute Myeloid L... Acute Lymphoid ... | 18 Years - 99 Years | Pfizer | ||
| Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia | NCT02345915 | Leukemia, Myelo... Acute Lymphoid ... | Blood sample Electrocardiogr... | 18 Years - 30 Years | Institut Paoli-Calmettes | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | NCT04167683 | Hematologic Dis... Chronic Myeloid... Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Non Hodgkin Lym... Stem Cell Trans... Chronic Lymphoc... | No intervention | 18 Years - | Rigshospitalet, Denmark | |
| Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | NCT01720264 | Acute Myeloid L... Acute Lymphoid ... Hematopoetic My... Leukemia, Myelo... Lymphoma, Non-H... | Sitagliptin | 18 Years - 60 Years | Indiana University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
